Compounds > 6-amino-1-hydroxyhexane-1,1-diphosphonate

Page last updated: 2024-08-25

6-amino-1-hydroxyhexane-1,1-diphosphonate and deoxypyridinoline

6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with deoxypyridinoline in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (37.50)	18.2507
2000's	5 (62.50)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chambers, TJ; Gallagher, AC; Laversuch, CJ; Tobias, JH	1
Laversuch, CV; Robins, SP; Tobias, JH; Wilson, N	1
Casciari, C; Cristallini, S; Filipponi, P; Gregorio, F; Policani, G	1
Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G	1
Bulleri, M; Di Munno, O; Giordani, R; Mazzantini, M; Metelli, MR	1
Adami, S; Braga, V; Colapietro, F; Fracassi, E; Gatti, D; Rossini, M; Tatò, L	1
Anastasi, G; Atteritano, M; Catalano, A; Frisina, N; Gaudio, A; Lasco, A; Melloni, D; Morabito, N; Trifiletti, A	1
Anastasi, G; Franchina, F; Frisina, N; Galì, A; Gaudio, A; Magno, C; Maisano, D; Melloni, D; Morabito, N	1

Trials

7 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and deoxypyridinoline

Article	Year
Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. British journal of rheumatology, 1996, Volume: 35, Issue:7 Topics: Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Diseases, Metabolic; Creatinine; Diphosphonates; Estrogens; Female; Humans; Middle Aged; Osteocalcin; Postmenopause; Progestins; Time Factors	1996
Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Bone, 1998, Volume: 23, Issue:6 Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Bone Resorption; Clodronic Acid; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Drug Resistance; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pain; Peptides; Recurrence; Treatment Outcome	1998
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:3 Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diphosphonates; Female; Humans; Infusions, Intravenous; Isoenzymes; Osteoporosis, Postmenopausal; Pamidronate; Structure-Activity Relationship; Triglycerides	2000
Single infusion of neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: effects on disease activity and bone resorption markers. Aging clinical and experimental research, 2002, Volume: 14, Issue:3 Topics: Aged; Amino Acids; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Bone Resorption; C-Reactive Protein; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Hydroxyproline; Male; Middle Aged; Peptides	2002
Intravenous neridronate in adults with osteogenesis imperfecta. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2003, Volume: 18, Issue:1 Topics: Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Collagen; Collagen Type I; Diphosphonates; Female; Fractures, Bone; Humans; Infusions, Intravenous; Male; Middle Aged; Osteogenesis Imperfecta; Peptides	2003
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:11 Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate	2004
Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. European urology, 2005, Volume: 47, Issue:5 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Anilides; Biomarkers; Bone Density; Calcium; Chromatography, High Pressure Liquid; Diphosphonates; Drug Therapy, Combination; Estradiol; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Nitriles; Osteoporosis; Parathyroid Hormone; Phosphorus; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome; Vitamin D	2005

Other Studies

1 other study(ies) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and deoxypyridinoline

Article	Year
Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. Calcified tissue international, 1996, Volume: 59, Issue:5 Topics: Administration, Oral; Amino Acids; Chromatography, High Pressure Liquid; Diphosphonates; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause	1996